CClinicalTrials.gg
Status unknownNCT03286920Updated Jan 23, 2018

Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer

An observational study in Esophageal Cancer, sponsored by Peking University Cancer Hospital & Institute. Status unknown at 23 sites in China. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Peking University Cancer Hospital & Institute · Observational

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
Up to 80 Years
Sex
All
01

Study summary

This clinical trial is designed to be a multi-center prospective observational study which shall compare the effect of different postoperative home nutrition modes on recent nutritional index (weight/BMI) of patients with esophageal cancer and recent outcomes. Different postoperative home nutrition modes adopted in this study includes oral natural diet, oral nutrition supplement and tube feeding.

Read the detailed description

STUDY BACKGROUND Esophageal cancer is a common cancer in China and due to its influence on diet intake, patients with esophageal cancer are often combined with nutrition deficiency, which causes relatively high nutrition risk to treatment. Studies conducted by Martin et al showed that the degree of body weight loss in patients with malignancy is related to BMI level and prognosis. The patients with severe body weight loss and low BMI have poor prognosis, especially for patients with esophageal cancer.

At present, perioperative nutrition support for patients with esophageal cancer has been recognized and has been recommended as routine in 2017 NCCN guideline. How to implement good home nutrition within one month after patient discharge and recover nutrition index as soon as possible has become a focus for esophageal surgeon.

Many clinical trials have already investigated enteral nutrition support approach during anti-cancer treatment period in patients with malignancy. However, only a few clinical trials are good designed. Therefore the investigators hope to via this multi-center prospective observational study to provide evidence for this question.

OBJECTIVES:

  1. To explore the relationship between postoperative home nutrition support treatment approach and nutritional status of patients with esophageal cancer;
  2. To explore the relationship between postoperative home nutrition support treatment approach and recent prognosis in patients with esophageal cancer;
  3. To promote the standardized application of postoperative home nutrition support treatment for patients with esophageal cancer.\

OUTLINE:

Included patients shall be divided into three groups according to the treatment plan of all centers, including oral natural diet, oral nutrition supplement and tube feeding. As for patients in oral natural diet group, the patients shall receive oral natural diet. As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d. As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding enteral supplement providing 750-1500kcal/d.

All the included patients shall be followed up weekly within 1-3 weeks after discharge via telephone, at Day 30 after discharge and at Day 90 after discharge to assess the effectiveness and safety of different home nutrition supplement approaches.

PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.

02

Conditions studied

  • Esophageal Cancer

Keywords

  • home nutrition
  • BMI
  • postoperative
  • body weight
03

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with esophageal cancer who undergo surgery

Inclusion criteria

  • Age below 80 years old;
  • Esophageal cancer;
  • Radical surgery;
  • Normal gastrointestinal function

Exclusion criteria

Exclusion Criteria:

  • Patients with diabetes and poor blood glucose control;
  • Patients with severe postoperative complications;
  • Patients who can't tolerate lactose;
  • Patients who decline inclusion and follow-ups
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Oral natural diet

    As for patients in oral natural diet group, the the participants shall receive oral natural diet.

  • Oral nutrition supplement group

    As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.

    Dietary Supplement: Oral nutrition supplement

  • Tube feeding nutrition supplement group

    As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.

    Dietary Supplement: Tube feeding nutrition supplement

Interventions

  • Dietary supplementOral nutrition supplement

    As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.

  • Dietary supplementTube feeding nutrition supplement

    As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.

05

What researchers measure

Primary outcomes

  1. Percentage of 5% body weight loss on Day 30

    Percentage of 5% body weight loss on Day 30 compared to the body weight at discharge

    Time frame: Day 30 after discharge

Secondary outcomes

  1. Completion ratio of different nutrition support approaches

    Completion ratio of different nutrition support approaches

    Time frame: Day 30 after discharge

  2. Quality of life assessment using EORTC QLQ-C30 scale and QLQ-OG25 scale

    Assessment on patients' quality of life using EORTC QLQ-C30 scale and QLQ-OG25 scale in different nutrition support approach groups and investigate the relationship between different nutrition support approaches and patients' quality of life

    Time frame: Day30 and Day 90

  3. Complications of home enteral nutrition support

    Assessment on complications of home enteral nutrition support

    Time frame: Day30

  4. Delay and interruption ratio of adjuvant treatment

    Delay and interruption ratio of adjuvant treatment including whether chemotherapy and radiotherapy can be implemented on time

    Time frame: Day 30 and Day 90

  5. Re-hospitalization ratio

    Re-hospitalization ratio within 90 days after discharge

    Time frame: Day 90

06

Study locations

23 of 23 sites recruiting
  • First Affiliated Hospital Bengbu Medical College
    Bengbu, Anhui, China
    Recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing, China
    Recruiting
  • China-Japan Friendship Hospital
    Beijing, Beijing, China
    Recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing, China
    Recruiting
  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
    Chongqing, Chongqing, China
    Recruiting
  • Union hospital of Fujian Medical University
    Fuzhou, Fujian, China
    Recruiting
  • Sun Yat-sen University Cancer Hospital
    Guangdong, Guangdong, China
    Recruiting
  • Guangzhou General Hospital of Guangzhou Military Command
    Guangzhou, Guangdong, China
    Recruiting
  • Hebei Medical University Fourth Hospital
    Shijiazhuang, Hebei, China
    Recruiting
  • The Third Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    Recruiting
  • Anyang Tumor Hospital
    Anyang, Henan, China
    Recruiting
  • Tongji Hospital
    Wuhan, Hubei, China
    Recruiting
  • Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
  • First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
  • Liaoning Tumor Hospital & Institute
    Shenyang, Liaoning, China
    • Hongxu Liu, M.D. · Contact · +86 13840004476
    Recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting
  • Shandong Provincial Hospital
    Jinan, Shandong, China
    Recruiting
  • Fudan University Cancer Hospital
    Shanghai, Shanghai, China
    Recruiting
  • Shanghai Chest Hospital
    Shanghai, Shanghai, China
    Recruiting
  • Shanxi Province Cancer Hospital
    Taiyuan, Shanxi, China
    Recruiting
  • First People's Hospital of Yunan province
    Kunming, Yunan, China
    Recruiting
  • Zhejiang Cancer Hospital
    Hanzhou, Zhejiang, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03286920
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborators
Sun Yat-sen University, Zhejiang Cancer Hospital, Shanghai Chest Hospital, China-Japan Friendship Hospital, Fudan University, Shandong Provincial Hospital, Hebei Medical University Fourth Hospital, Anyang Tumor Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Bengbu Medical University, Tongji Hospital, Shanxi Province Cancer Hospital, The Third Affiliated Hospital of Harbin Medical University, Liaoning Cancer Hospital & Institute, Wuhan General Hospital of Guangzhou Military Command, Second Xiangya Hospital of Central South University, The First Hospital of Jilin University, Chinese PLA General Hospital, Hunan Provincial People's Hospital, Fujian Cancer Hospital, Qilu Hospital of Shandong University, Union hospital of Fujian Medical University, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Responsible party
Ke-Neng Chen, MD, PhD, FRCS (Doctor, Peking University Cancer Hospital & Institute) — Principal investigator
First posted
Sep 19, 2017
Start date
Sep 20, 2017
Primary completion
Sep 2018 (estimated)
Completion
Sep 2018 (estimated)
Last update
Jan 23, 2018

Study contacts

Keneng Chen, M.D.
Contact
chenkeneng@bjmu.edu.cn
+86 13501085973
Liang Dai, M.D.
Contact
dailiangsharp_26@aliyun.com
+86 18610065191
Keneng Chen, M.D.
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion